We can’t show the full text here under this license.
COVID-19 mRNA vaccines may help tumors respond better to immune checkpoint therapy
Updated
Abstract
SARS-CoV-2 mRNA vaccines are associated with significantly improved median and three-year overall survival in cancer patients receiving .
- Preclinical models showed that SARS-CoV-2 mRNA vaccines led to a substantial increase in .
- Increased type I interferon enabled innate immune cells to activate CD8 T cells targeting tumour-associated antigens.
- Concomitant treatment with immune checkpoint inhibitors is necessary for maximal efficacy in tumours lacking pre-existing immunity.
- In humans, vaccination correlates included heightened type I interferon levels and increased PD-L1 expression on tumours.
- Vaccination with SARS-CoV-2 mRNA within 100 days of starting immune checkpoint inhibitors is linked to improved overall survival.
Simplified
Key numbers
26.67 months
Increase
Median for vaccinated patients with or melanoma.
37%
Expression Increase
Increase in tumor expression associated with COVID-19 vaccination.
mRNA Technology